Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)

SHE:002390 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	985.25	1,016	805.98	899.18	624.65	1,776
Cash & Short-Term Investments	985.25	1,016	805.98	899.18	624.65	1,776
Cash Growth	60.47%	26.00%	-10.37%	43.95%	-64.84%	43.76%
Accounts Receivable	2,775	2,691	3,036	3,091	3,082	2,666
Other Receivables	322.94	320.24	324.63	448.8	600.56	542.24
Receivables	3,098	3,012	3,361	3,540	3,682	3,209
Inventory	1,015	1,060	1,001	1,033	935.71	843.39
Prepaid Expenses	-	0.02	0.03	0.02	0.02	0
Other Current Assets	176.53	164.39	243.61	334.34	333.72	262.83
Total Current Assets	5,275	5,252	5,412	5,806	5,576	6,091
Property, Plant & Equipment	2,398	2,426	2,518	2,672	2,706	2,323
Long-Term Investments	337.47	337.47	340.47	343.84	347.41	223.03
Goodwill	603.75	603.75	603.75	607.35	607.35	605.54
Other Intangible Assets	186.39	189.54	180.18	204.37	217.65	219.56
Long-Term Deferred Tax Assets	81.35	81.87	74.14	62.81	55.61	46.51
Long-Term Deferred Charges	65.89	69.3	81.84	97.21	118.36	153.19
Other Long-Term Assets	68.18	68.57	35	-	-	-
Total Assets	9,016	9,028	9,245	9,794	9,629	9,662
Accounts Payable	872.33	927.97	903.15	977.24	993.43	788.57
Accrued Expenses	18.74	37.15	35.27	32.99	40.93	34.23
Short-Term Debt	550.08	603.54	809.86	1,368	1,390	3,410
Current Portion of Leases	3.76	3	4.4	2.51	-	-
Current Income Taxes Payable	24.63	7.6	21.09	17.21	17.79	16.46
Current Unearned Revenue	29.33	25.94	27.98	33.24	55.44	39.62
Other Current Liabilities	247.93	201.68	256.82	255.56	256.6	181.45
Total Current Liabilities	1,747	1,807	2,059	2,687	2,755	4,470
Long-Term Debt	230	160	-	-	-	-
Long-Term Leases	18.8	21	21.12	22.02	24.81	-
Long-Term Unearned Revenue	19.06	19.52	22.04	18.89	20.38	22.88
Long-Term Deferred Tax Liabilities	0.7	0.73	0.84	0.56	-	-
Other Long-Term Liabilities	0.28	0.29	0.31	0.32	0.34	0.35
Total Liabilities	2,016	2,008	2,103	2,729	2,800	4,494
Common Stock	1,944	1,944	1,944	1,944	2,027	1,667
Additional Paid-In Capital	4,403	4,403	4,403	4,402	4,693	3,624
Retained Earnings	604.67	563.43	633.34	462.74	354.99	82.17
Treasury Stock	-199.93	-199.93	-127.49	-	-455.38	-455.38
Total Common Equity	6,751	6,710	6,852	6,808	6,620	4,918
Minority Interest	249.23	309.87	289.69	256.55	208.74	250.16
Shareholders' Equity	7,001	7,020	7,142	7,065	6,829	5,169
Total Liabilities & Equity	9,016	9,028	9,245	9,794	9,629	9,662
Total Debt	802.65	787.55	835.38	1,393	1,415	3,410
Net Cash (Debt)	182.6	227.97	-29.4	-493.42	-790.6	-1,634
Net Cash Per Share	0.09	0.11	-0.02	-0.26	-0.43	-1.04
Filing Date Shares Outstanding	1,896	1,896	1,907	1,944	1,944	1,584
Total Common Shares Outstanding	1,896	1,896	1,907	1,944	1,944	1,584
Working Capital	3,528	3,445	3,353	3,119	2,822	1,621
Book Value Per Share	3.56	3.54	3.59	3.50	3.41	3.11
Tangible Book Value	5,961	5,917	6,068	5,997	5,795	4,093
Tangible Book Value Per Share	3.14	3.12	3.18	3.08	2.98	2.58
Buildings	-	2,517	2,516	2,578	2,396	1,905
Machinery	-	1,716	1,722	1,697	1,641	1,550
Construction In Progress	-	145.02	58.06	24.98	92.38	122.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.